{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:29:55Z","timestamp":1778729395500,"version":"3.51.4"},"reference-count":55,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1704,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1111\/j.1751-7133.2010.00209.x","type":"journal-article","created":{"date-parts":[[2011,1,28]],"date-time":"2011-01-28T02:16:40Z","timestamp":1296181000000},"page":"42-46","source":"Crossref","is-referenced-by-count":54,"title":["Use of Metabolomic Profiling in the Study of Arachidonic Acid Metabolism in Cardiovascular Disease"],"prefix":"10.1111","volume":"17","author":[{"given":"Ning","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd R.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Padmini","family":"Sirish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce D.","family":"Hammock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nipavan","family":"Chiamvimonvat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,1,27]]},"reference":[{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1161\/CIRCULATIONAHA.105.171600","article-title":"Heart disease and stroke statistics-2007 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee","volume":"113","author":"Rosamond","year":"2006","journal-title":"Circulation"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev.physiol.65.092101.142243","article-title":"Cardiac hypertrophy: the good, the bad, and the ugly","volume":"65","author":"Frey","year":"2003","journal-title":"Annu Rev Physiol"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/nm802","article-title":"Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics","volume":"8","author":"Brindle","year":"2002","journal-title":"Nat Med"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1172\/JCI35111","article-title":"Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury","volume":"118","author":"Lewis","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2217\/14622416.6.7.691","article-title":"The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements","volume":"6","author":"Lindon","year":"2005","journal-title":"Pharmacogenomics"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1013713905833","article-title":"Metabolomics-the link between genotypes and phenotypes","volume":"48","author":"Fiehn","year":"2002","journal-title":"Plant Mol Biol"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1172\/JCI34138","article-title":"Metabolomic analysis of the cerebrospinal fluid reveals changes in phospholipase expression in the CNS of SIV-infected macaques","volume":"118","author":"Wikoff","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.bcp.2009.10.025","article-title":"Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model","volume":"79","author":"Liu","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"17017","DOI":"10.1073\/pnas.1011278107","article-title":"Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events","volume":"107","author":"Liu","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jama.286.8.954","article-title":"Risk of cardiovascular events associated with selective COX-2 inhibitors","volume":"286","author":"Mukherjee","year":"2001","journal-title":"JAMA"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB12|cit12","first-page":"324","article-title":"Merck settles Vioxx lawsuits for $4.85\u2003billion","volume":"450","author":"Wadman","year":"2007","journal-title":"Nature"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1126\/science.1068711","article-title":"Role of prostacyclin in the cardiovascular response to thromboxane A(2)","volume":"296","author":"Cheng","year":"2002","journal-title":"Science"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1056\/NEJMp048288","article-title":"Coxibs and cardiovascular disease","volume":"351","author":"FitzGerald","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/bmj.330.7504.1366","article-title":"Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis","volume":"330","author":"Hippisley-Cox","year":"2005","journal-title":"Br Med J"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJM198706113162405","article-title":"Concurrent morning increase in platelet aggregability and the risk of myocardial-infarction and sudden cardiac death","volume":"316","author":"Tofler","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB17|cit17","first-page":"13","article-title":"Increased platelet aggregability in young patients with stroke. Diagnosis and therapy","volume":"32","author":"Kalendovsky","year":"1975","journal-title":"Neurology"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1136\/bmj.290.6484.1767","article-title":"Shortened bleeding-time in acute myocardial-infarction and its relation to platelet mass","volume":"290","author":"Milner","year":"1985","journal-title":"Br Med J"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1055\/s-0038-1647494","article-title":"Bleeding time and platelet volume in acute myocardial infarction: a 2\u2003year follow-up study","volume":"59","author":"Dalby Kristensen","year":"1988","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1126\/science.285.5431.1276","article-title":"Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids","volume":"285","author":"Node","year":"1999","journal-title":"Science"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0952-3278(97)90412-9","article-title":"Cytochrome P450 metabolites of arachidonic acid: rapid incorporation and hydration of 14,15-epoxyeicosatrienoic acid in arterial smooth muscle cells","volume":"57","author":"Fang","year":"1997","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.bjp.0701778","article-title":"Endothelium-dependent relaxation and hyperpolarization in guinea-pig coronary artery: role of epoxyeicosatrienoic acid","volume":"124","author":"Eckman","year":"1998","journal-title":"Br J Pharmacol"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.prostaglandins.2006.05.004","article-title":"Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs)","volume":"82","author":"Inceoglu","year":"2007","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.abb.2004.10.009","article-title":"Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids","volume":"433","author":"Spiecker","year":"2005","journal-title":"Arch Biochem Biophys"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1152\/physrev.00021.2001","article-title":"P-450 metabolites of arachidonic acid in the control of cardiovascular function","volume":"82","author":"Roman","year":"2002","journal-title":"Physiol Rev"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1161\/01.CIR.0000143832.91812.60","article-title":"Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2","volume":"110","author":"Spiecker","year":"2004","journal-title":"Circulation"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1161\/01.RES.0000139436.89654.c8","article-title":"Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42\/p44 MAPK pathway","volume":"95","author":"Seubert","year":"2004","journal-title":"Circ Res"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"H37","DOI":"10.1152\/ajpheart.00983.2008","article-title":"Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity","volume":"297","author":"Zhang","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1161\/01.RES.87.11.992","article-title":"Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids","volume":"87","author":"Yu","year":"2000","journal-title":"Circ Res"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2174\/156802609788340805","article-title":"Soluble epoxide hydrolase, a target with multiple opportunities for cardiovascular drug discovery","volume":"9","author":"Marino","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB31|cit31","first-page":"253","article-title":"Soluble epoxide hydrolase: a new target for cardioprotection","volume":"10","author":"Gross","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/FJC.0b013e3181506445","article-title":"The soluble epoxide hydrolase as a pharmaceutical target for hypertension","volume":"50","author":"Chiamvimonvat","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1527-3466.2006.00169.x","article-title":"Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors","volume":"24","author":"Imig","year":"2006","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-2362.2006.01634.x","article-title":"Emerging role of epoxyeicosatrienoic acids in coronary vascular function","volume":"36","author":"Larsen","year":"2006","journal-title":"Eur J Clin Invest"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1073\/pnas.0811022106","article-title":"Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy","volume":"106","author":"Ai","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.yjmcc.2008.09.711","article-title":"Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model","volume":"46","author":"Batchu","year":"2009","journal-title":"J Mol Cell Cardiol"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"H2128","DOI":"10.1152\/ajpheart.00428.2008","article-title":"Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo","volume":"295","author":"Motoki","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/FJC.0b013e318185fa3c","article-title":"Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model","volume":"52","author":"Ulu","year":"2008","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.2741\/2942","article-title":"Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension","volume":"13","author":"Li","year":"2008","journal-title":"Front Biosci"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"H2838","DOI":"10.1152\/ajpheart.00186.2008","article-title":"Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart","volume":"294","author":"Gross","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/01.RES.0000237390.92932.37","article-title":"Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function","volume":"99","author":"Seubert","year":"2006","journal-title":"Circ Res"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1161\/hy0202.103788","article-title":"Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension","volume":"39","author":"Imig","year":"2002","journal-title":"Hypertension"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"18733","DOI":"10.1073\/pnas.0609158103","article-title":"Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors","volume":"103","author":"Xu","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.yjmcc.2009.08.017","article-title":"Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: insight gained using metabolomic approaches","volume":"47","author":"Li","year":"2009","journal-title":"J Mol Cell Cardiol"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11897-008-0012-2","article-title":"Immune modulation: role of the inflammatory cytokine cascade in the failing human heart","volume":"5","author":"Satoh","year":"2008","journal-title":"Curr Heart Fail Rep"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cardiores.2004.02.005","article-title":"Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure","volume":"63","author":"Sekiguchi","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/ng.129","article-title":"Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease","volume":"40","author":"Monti","year":"2008","journal-title":"Nat Genet"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"13646","DOI":"10.1073\/pnas.0605908103","article-title":"Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors","volume":"103","author":"Schmelzer","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"9772","DOI":"10.1073\/pnas.0503279102","article-title":"Soluble epoxide hydrolase is a therapeutic target for acute inflammation","volume":"102","author":"Schmelzer","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s11745-004-1317-0","article-title":"Dietary fish oil dose- and time-response effects on cardiac phospholipid fatty acid composition","volume":"39","author":"Owen","year":"2004","journal-title":"Lipids"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0022-3565(25)10628-9","article-title":"Epoxygenase metabolites of docosahexaenoic and eicosapentaenoic acids inhibit platelet aggregation at concentrations below those affecting thromboxane synthesis","volume":"274","author":"VanRollins","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1124\/jpet.303.2.768","article-title":"Cytochrome p-450 epoxygenase metabolites of docosahexaenoate potently dilate coronary arterioles by activating large-conductance calcium-activated potassium channels","volume":"303","author":"Ye","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1194\/jlr.M006007","article-title":"Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids","volume":"51","author":"Morisseau","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1161\/01.HYP.0000208299.62535.58","article-title":"Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling","volume":"47","author":"Pokreisz","year":"2006","journal-title":"Hypertension"},{"key":"10.1111\/j.1751-7133.2010.00209.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.resuscitation.2007.06.031","article-title":"Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation","volume":"76","author":"Hutchens","year":"2008","journal-title":"Resuscitation"}],"container-title":["Congestive Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1751-7133.2010.00209.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T06:25:03Z","timestamp":1740896703000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1751-7133.2010.00209.x"}},"subtitle":["study of arachidonic acid metabolism in CV disease"],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1751-7133.2010.00209.x","relation":{},"ISSN":["1527-5299"],"issn-type":[{"value":"1527-5299","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}